Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,378 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT07601334RecruitingPhase 1
Testing HF50 safety in advanced solid tumors
This Phase 1 trial tests a new drug called HF50 in people with advanced cancers that have spread or cannot be surgically removed. The goal is to see if HF50 is safe and whether it helps shrink tumors in patients whose cancer has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07595237RecruitingEarly Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Boston, MassachusettsAges 18 years+ - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06717022Recruiting
CHT102 for mesothelin-positive advanced solid tumors
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07586943RecruitingPhase 1/Phase 2
Study of SKB118 for advanced solid tumors
This study tests an experimental drug called SKB118 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT07584226RecruitingPhase 1
Testing RLY-8161 for advanced cancers with NRAS mutations
This trial tests a new drug called RLY-8161 in people with advanced solid tumors (cancer that has spread) that have a specific genetic mutation called NRAS. The drug is designed to target this mutation and may help slow or shrink tumors that haven't responded to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT06726564RecruitingPhase 1
Study of MT027 for malignant pleural effusion
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
BeijingAges 18 years+ - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT07561437RecruitingEarly Phase 1
NK521 infusion for advanced cancer with fluid buildup
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,378 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.